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A B S T R A C T
Background
Preoperative anaemia is common and occurs in 5% to 76% of patients preoperatively. It is associated with an increased risk of perioper-
ative allogeneic blood transfusion, longer hospital stay, and increased morbidity and mortality. Iron deficiency is one of the most com-
mon causes of anaemia. Oral and intravenous iron therapy can be used to treat anaemia. Parenteral iron preparations have been shown
to be more effective in conditions such as inflammatory bowel disease, chronic heart failure and postpartum haemorrhage due to rapid
correction of iron stores. A limited number of studies has investigated iron therapy for the treatment of preoperative anaemia. The aim
of this Cochrane Review is to summarise the evidence for iron supplementation, both enteral and parenteral, for the management of pre-
operative anaemia.
Objectives
To evaluate the effects of preoperative iron therapy (enteral or parenteral) in reducing the need for allogeneic blood transfusions in
anaemic patients undergoing surgery.
Search methods
We ran the search on 30 July 2018. We searched the Cochrane Injuries Group's Specialised Register, Cochrane Central Register of Controlled
Trials (CENTRAL, the Cochrane Library), Ovid MEDLINE(R), Ovid MEDLINE(R) In-Process & Other Non-Indexed Citations, Ovid MEDLINE(R)
Daily and Ovid OLDMEDLINE(R), Embase Classic and Embase (Ovid), CINAHL Plus (EBSCO), PubMed, and clinical trials registries, and we
screened reference lists. We ran a top-up search on 28 November 2019; one study is now awaiting classification.
Selection criteria
We included all randomised controlled trials (RCTs) that compared preoperative iron monotherapy to placebo, no treatment, standard
care or another form of iron therapy for anaemic adults undergoing surgery. We defined anaemia as haemoglobin values less than 13 g/
dL for males and 12 g/dL for non-pregnant females.
Data collection and analysis
Two review authors collected data and a third review author checked all collected data. Data were collected on the proportion of patients
who receive a blood transfusion, the amount of blood transfused per patient (units), quality of life, ferritin levels and haemoglobin levels,
measured as continuous variables at the following predetermined time points: pretreatment (baseline), preoperatively but postinterven-
tion, and postoperatively. We performed statistical analysis using the Cochrane software, Review Manager 5. We summarised outcome
data in tables and forest plots. We used the GRADE approach to describe the quality of the body of evidence.
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Main results
Six RCTs, with a total of 372 participants, evaluated preoperative iron therapy to correct anaemia before planned surgery. Four studies
compared iron therapy (either oral (one study) or intravenous (three studies)) with no treatment, placebo or usual care, and two studies
compared intravenous iron therapy with oral iron therapy. Iron therapy was delivered over a range of periods that varied from 48 hours
to three weeks prior to surgery. The 372 participants in our analysis fall far short of the 819 required - as calculated by our information
size calculation - to detect a 30% reduction in blood transfusions. Five trials, involving 310 people, reported the proportion of participants
who received allogeneic blood transfusions.
Meta-analysis of iron therapy versus placebo or standard care showed no difference in the proportion of participants who received a blood
transfusion (risk ratio (RR) 1.21, 95% confidence interval (CI) 0.87 to 1.70; 4 studies, 200 participants; moderate-quality evidence). Only
one study that compared oral versus intravenous iron therapy measured this outcome, and reported no difference in risk of transfusion
between groups.
There was no difference between the iron therapy and placebo/standard care groups for haemoglobin level preoperatively at the end of the
intervention (mean difference (MD) 0.63 g/dL, 95% CI -0.07 to 1.34; 2 studies, 83 participants; low-quality evidence). However, intravenous
iron therapy produced an increase in preoperative postintervention haemoglobin levels compared with oral iron (MD 1.23 g/dL, 95% CI
0.80 to 1.65; 2 studies, 172 participants; low-quality evidence). Ferritin levels were increased by intravenous iron, both when compared to
standard care ((MD 149.00, 95% CI 25.84 to 272.16; 1 study, 63 participants; low-quality evidence) or to oral iron (MD 395.03 ng/mL, 95%
CI 227.72 to 562.35; 2 studies, 151 participants; low-quality evidence).
Not all studies measured quality of life, short-term mortality or postoperative morbidity. Some measured the outcomes, but did not report
the data, and the studies which did report the data were underpowered. Therefore, uncertainty remains regarding these outcomes. The
inclusion of new research in the future is very likely to change these results.
Authors' conclusions
The use of iron therapy for preoperative anaemia does not show a clinically significant reduction in the proportion of trial participants
who received an allogeneic blood transfusion compared to no iron therapy. Results for intravenous iron are consistent with a greater
increase in haemoglobin and ferritin when compared to oral iron, but do not provide reliable evidence. These conclusions are drawn from
six studies, three of which included very small numbers of participants. Further, well-designed, adequately powered, RCTs are required
to determine the true effectiveness of iron therapy for preoperative anaemia. Two studies are currently in progress, and will include 1500
randomised participants.
P L A I N   L A N G U A G E   S U M M A R Y
Iron treatment for low red blood cell count prior to surgery
Review question: we reviewed the evidence for giving iron treatment to people with a low red blood cell count (anaemia) before they
had major surgery, to see if it reduced their need for blood transfusions around the time of surgery. We found six studies that looked at
this question.
Background: anaemia is a common problem for people about to have surgery. Anaemia can cause dizziness, shortness of breath and lack
of energy, as well as increase the risks of surgery and of blood transfusion. Anaemia is commonly due to lack of iron, and iron treatment -
with tablets or injections - has been shown to be effective in other situations for treating anaemia. Limited research has looked at whether
iron treatment works before surgery.
Search date: on 30 July 2018 we conducted a wide ranging search of the medical literature to identify relevant medical studies.
Study characteristics: we looked at adults with anaemia who were due to have an operation, who received iron treatment or usual care, or
a 'pretend' iron treatment (placebo) prior to their surgery. We also compared different forms of iron therapy with each other. We included
six studies and a total of 372 participants.
Key results: iron treatment did not reduce the risk of blood transfusion. There is currently insufficient evidence to say whether iron therapy
given before surgery prevents transfusions. To date, too few studies involving too small a number of people have been undertaken, and
it is not yet possible to obtain a reliable result for the effects of this treatment.
Quality of evidence: the major limitation in study design for all trials was the small size of the sample groups. More research in larger, well-
designed trials is needed before a definitive answer can be given about whether iron therapy before surgery is helpful. The Cochrane Review
authors judged that five of the six studies included in this review were at a low risk of bias (and so their results are likely to be reliable).
This was despite a lack of blinding of participants in five of the trials (which would usually decrease the reliability of the evidence), as the
measurement used to assess how well the therapy had worked (blood haemoglobin level) was unlikely to be influenced by the participant
or investigator knowing which treatment had been received. The results of one study are at a high risk of bias because participants who
did not take 80% of their assigned treatment were not included in the analysis.
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Overall the quality of evidence is low (according to the GRADE criteria). When additional research becomes available in the future, it is
likely to change the results obtained in this review.
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S U M M A R Y   O F   F I N D I N G S
 
Summary of findings for the main comparison.   Iron therapy compared to placebo, no treatment or standard care for preoperative anaemia
Iron therapy compared to placebo, no treatment or standard care for preoperative anaemia
Patient or population: people with preoperative anaemia awaiting major surgery
Settings: hospital
Intervention: iron therapy
Comparison: placebo, no treatment or standard care
Illustrative comparative risks* (95% CI)
Assumed risk Corresponding risk
Outcomes













Proportion of participants who re-
ceived a blood transfusion









Any validated measure of quality
of life (measured by SF36)
6 ± 17 8 ± 18 - 72 (1 study) ⊕⊝⊝⊝
Very lowb
 
Haemoglobin levels at end of pre-
operative treatment (g/dL)




bin levels in the inter-
vention groups was
0.63 g/dL higher










ment and surgery (g/dL)




bin levels in the inter-
vention groups was
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Ferritin at the end of preoperative
treatment (ng/mL)
The mean ferritin level in the con-
trol group was
99 ng/mL
The mean ferritin lev-







































































































































(26 higher to 272 high-
er)
*The basis for the assumed risk (e.g. the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% confidence interval) is
based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI).
CI: confidence interval; MD: mean difference; RR: risk ratio; SF-36: Short-Form Survey 36
GRADE Working Group grades of evidence
High quality: further research is very unlikely to change our confidence in the estimate of effect.
Moderate quality: further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.
Low quality: further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.
Very low quality: we are very uncertain about the estimate.
aDowngraded 2 levels for imprecision with only four randomised control trials including subsets of anaemic participants, resulting in a small number of participants.
bDowngraded 3 levels for imprecision with only one study, with a small number of participants and no blinding.
cDowngraded 2 levels for imprecision with only one study with a small number of participants available.
 
 
Summary of findings 2.   Intravenous iron therapy compared to oral iron therapy for preoperative anaemia
Intravenous iron therapy compared to oral iron therapy for preoperative anaemia
Patient or population: people with preoperative anaemia awaiting major surgery
Settings: hospital
Intervention: intravenous iron therapy
Comparison: oral iron therapy
















Proportion of participants who received a
blood transfusion
No data available No data avail-
able
- - -  
Any validated measure of quality of life No data available No data avail-
able
- - -  
Haemoglobin levels at end of preopera-
tive treatment (g/dL)
The mean haemoglobin level in the
















































































































































Haemoglobin levels post-treatment and
surgery (g/dL)
No data available No data avail-
able
- - -  
Ferritin preoperatively postintervention
(ng/L)














151 (2 studies) ⊕⊕⊝⊝
Lowa
 
*The basis for the assumed risk (e.g. the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% confidence interval) is
based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI).
CI: confidence interval;IV: intravenous; MD: mean difference
GRADE Working Group grades of evidence
High quality: further research is very unlikely to change our confidence in the estimate of effect.
Moderate quality: further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.
Low quality: further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.
Very low quality: we are very uncertain about the estimate.
a Downgraded twice overall: 1 level due to risk of bias (attrition bias), as the Kim 2009 study excluded participants with less than 80% compliance with therapy (compliance was
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B A C K G R O U N D
Description of the condition
'Anaemia' is defined as a total reduction in erythrocyte number, a
reduced amount of circulating haemoglobin, or a decreased circu-
lating red blood cell mass (Perkins 2006), that results in a pathologi-
cal state where the oxygen-carrying capacity of blood is insufficient
to meet physiological demand (Varat 1972). The World Health Orga-
nization (WHO) defines anaemia as a haemoglobin level of less than
12 g/dL in non-pregnant adult women, less than 11 g/dL in preg-
nant adult women, and less than 13 g/dL in adult men. Anaemia is a
common finding in preoperative patients, with a prevalence rang-
ing from 5% to 76% depending on the age of the patient, the nature
of the condition, and operation planned (Shander 2004). The most
common form of anaemia is caused by iron deficiency, which can
occur following excessive losses of blood, such as chronic haemor-
rhage, or inadequate iron intake (Piednoir 2011).
Anaemia can cause symptoms such as dizziness, shortness of
breath, angina and lethargy. Anaemia in a preoperative setting
is associated with an increased requirement for perioperative
blood transfusion (Benoist 2001). In patients undergoing colorec-
tal surgery, preoperative anaemia is an independent risk factor for
postoperative complications and a longer postoperative hospital
stay (Leichtle 2011). Other studies have shown that perioperative
anaemia is associated with an increased risk of perioperative infec-
tion and mortality (Dunne 2002).
Description of the intervention
Oral iron supplementation and allogeneic blood transfusion are
the current standard treatments for preoperative anaemia. Preop-
erative, oral iron supplementation has been investigated in col-
orectal surgery (Lidder 2007; Quinn 2010), and orthopaedic surgery
(Lachance 2011), with mixed results. The treatment is cheap, wide-
ly available, and easily administered. However, oral iron is associ-
ated with a number of gastrointestinal side effects in up to 52% of
recipients, which is 2.6 times more than intravenous iron (Tolkien
2015). These include abdominal pain, constipation, diarrhoea and
dyspepsia (Tolkien 2015). Non-compliance as a result of these side
effects is a common problem (Tolkien 2015). Oral iron supplemen-
tation may also be insufficient to compensate for ongoing blood
losses, or low serum iron levels caused by hepcidin-mediated re-
duced intestinal absorption and storage of iron by macrophages,
both of which result from inflammation (Ganz 2003).
Parenteral iron was first introduced in the early 20th century in the
form of intramuscular and subcutaneous injections (Heath 1932).
However, these early formulations caused severe toxic reactions,
which led to their disuse. Towards the latter half of the 20th cen-
tury, high-molecular-weight iron dextran was introduced for both
intravenous and intramuscular use, however, this has since been
phased out due to reports of fatal anaphylactic-type reactions
caused by the instability of the molecule (Chertow 2004), as well
as the formation of antidextran antibodies. It has been replaced
with low-molecular-weight iron dextran and other newer formula-
tions of intravenous iron, such as iron sucrose, ferric gluconate, fer-
umoxytol, ferric carboxymaltose and iron isomaltoside.
There has been major progress in the development of newer for-
mulations of intravenous iron. Previously, iron sucrose, a safer for-
mulation that was not associated with anaphylactic-type reactions,
had to be given in maximum doses of 200 mg for each infusion,
thus requiring several small-dose infusions to achieve the calculat-
ed iron deficit. Newer agents, such as ferric carboxymaltose and
iron isomaltoside have now been developed; these allow total dose
infusion, have much higher maximum approved doses, and have
not been associated with anaphylactic-type reactions (Auerbach
2010).
Most research around the use of intravenous iron has centred
on the treatment of anaemia in inflammatory bowel disease and
chronic kidney disease. Early studies have shown that intravenous
iron is effective for treating anaemia in inflammatory bowel dis-
ease, with a quicker result than oral iron and fewer side effects,
which is an important factor for ensuring compliance (Kulnigg
2008). The use of intravenous iron in anaemic patients with chron-
ic heart failure has been shown to improve symptoms and quality
of life significantly (Anker 2009; Okonko 2008). In women with post-
partum iron deficiency anaemia, intravenous iron has been shown
to be safe, and at least as effective as oral iron, but with fewer
gastrointestinal side effects (Breymann 2008; Seid 2008). Kim 2009
showed that intravenous iron was more effective than oral iron in
the treatment of preoperative anaemia in women with menorrha-
gia. The use of intravenous iron in patients with chronic kidney dis-
ease is more effective than oral iron, and has fewer side effects
(Qunibi 2011).
However, only a limited number of studies has looked at the use of
intravenous iron for anaemia in a preoperative setting, and these
have mainly concerned orthopaedic surgery. Some of these stud-
ies have shown reduced risks of transfusion and infection with the
use of intravenous iron (Cuenca 2004; Garcia-Erce 2005). An ob-
servational study in patients undergoing major surgery (colorec-
tal cancer resections, hysterectomies and lower limb arthroplas-
ties) saw an average increase in haemoglobin level of 2 g/dL within
a three- to five-week period in patients who received intravenous
iron (Munoz 2014).
How the intervention might work
The bone marrow requires an internal iron turnover of 20 mg to 30
mg/day for erythropoiesis (formation of red blood cells). The body
absorbs 1 mg to 2 mg/day of dietary iron, despite the normal diet
containing 15 mg to 20 mg of iron. Ferrous sulphate is one of the
most commonly used oral iron supplements and a 200 mg tablet
contains 65 mg iron. Oral iron is absorbed mainly in the duodenum
where it is reduced into a ferrous state by the duodenal enterocytes
and exported via the iron exporter, ferroportin, into the circulation
bound to transferrin (Munoz 2009). Oral iron is absorbed most read-
ily on an empty stomach, however, this also increases the risk of
gastrointestinal side effects. Therefore, iron supplements are often
taken with food to minimise the side effects, although this may de-
crease the absorption by 40% to 66% (Swain 1996). Some drugs,
such as antacids, proton pump inhibitors and tetracyclines, also re-
duce iron absorption.
Current intravenous iron preparations consist of iron-carbohydrate
complexes. Following intravenous injection, the iron-carbohydrate
complex is taken up and phagocytosed by the reticuloendothelial
system and the remaining iron core is exported out of the cell and
transported for erythropoiesis and storage (Munoz 2009). New ery-
throcytes generated following the correction of iron-restricted ery-
thropoiesis in bone marrow have a longer half-life than transfused
erythrocytes (Kickler 1985).
Iron therapy for preoperative anaemia (Review)
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The use of intravenous iron bypasses the problems of poor absorp-
tion that arise with oral iron supplements. Intravenous iron is al-
so better tolerated, with far fewer gastrointestinal side effects than
oral iron (Qunibi 2011). Newer formulations of intravenous iron,
such as ferric carboxymaltose, can be given in large doses (up to
1000 mg) and studies have shown that intravenous iron results in a
more rapid rise in haemoglobin compared to oral iron supplemen-
tation (Qunibi 2011). Intravenous iron is now regarded as safe and
efficacious, especially in settings where oral iron is ineffective or in-
appropriate, such as in the presence of colitis or anaemia of chronic
disease from chronic inflammation (Auerbach 2014).
Why it is important to do this review
Preoperative anaemia is a predictor of perioperative allogeneic
blood transfusion (Shander 2004). Despite screening of blood prod-
ucts, allogeneic blood transfusion carries risks, such as viral trans-
mission, immunomodulation, allergic reactions and alloimmuni-
sation and increased infection (Vamvakas 2009). It has also been
independently associated with increased morbidity and mortali-
ty (Ferraris 2012; Glance 2011), and reduced cancer-related sur-
vival (Acheson 2012). Studies have also associated preoperative
anaemia with increased postoperative morbidity and mortality and
increased length of hospital stay (Acheson 2012; Beattie 2009; Gup-
ta 2013; Spahn 2010).
Oral iron is considered as first-line therapy if time and disease biol-
ogy allow for its use. It is cheap and effective in those that can ab-
sorb and tolerate it. When not tolerated, or if surgical intervention is
planned imminently, intravenous iron provides a method of man-
agement of anaemia that is increasingly used to treat preoperative
anaemia. It can be given as a large, single-dose regimen with fewer
gastrointestinal side effects than oral iron tablets (Auerbach 2014).
It is considerably more expensive than oral iron, and there are no
conclusive data to show that it reduces healthcare utilisation, or re-
garding its cost-effectiveness (Fragoulakis 2012). It is recommend-
ed for preoperative anaemia, especially if the proposed surgery is
urgent (due in less than six weeks) or where oral iron therapy is not
tolerated (Munoz 2017).
The aim of this Cochrane Review is to summarise the evidence for
use of iron supplementation, both oral and intravenous, for the
management of preoperative anaemia. The evidence from this re-
view will establish if there is justification for a large randomised
controlled trial to investigate the use of intravenous iron in preop-
erative anaemia.
O B J E C T I V E S
To evaluate the effects of preoperative iron therapy (enteral or par-
enteral) in reducing the need for allogeneic blood transfusions in
anaemic patients undergoing surgery.
M E T H O D S
Criteria for considering studies for this review
Types of studies
In order to be eligible for inclusion in the review, all RCTs taking
place after 2010 had to have been prospectively registered (Roberts
2015). All RCTs that published their results prior to 2010 were eligi-
ble for inclusion.
We considered all randomised controlled trials (RCTs) that com-
pared preoperative iron monotherapy to placebo, no treatment,
standard care or another form of iron therapy. Cross-over studies
were eligible for inclusion in the review, though we would use data
from the first phase only. Trials that used iron therapy in combina-
tion with other interventions were not eligible for inclusion in this
review.
Types of participants
Anaemic adults over the age of 18 years undergoing surgery. We
have defined anaemia as haemoglobin values less than 13 g/dL
for males and less than 12 g/dL for non-pregnant females (as per
the WHO standard guidelines). We accepted different criteria for
anaemia that were used in studies, if the study investigators provid-
ed a clear definition of what they considered constituted anaemia.
We included trials that did not specify anaemic participants, if there
was stratification of results to an anaemic subgroup. We did not in-
clude pregnant women in this review.
Types of interventions
We included trials that began the administration of iron between
the day of decision for surgery and the day before surgery. We in-
cluded trials with any dose, duration, formulation, or route (enteral
or parenteral) of iron therapy.
We compared an iron therapy intervention against placebo, no
treatment or standard care (as described in each trial protocol), or
between two iron therapy interventions. We excluded trials where
the effect of iron was combined with another co-intervention (for
example erythropoiesis-stimulating agents).
Types of outcome measures
Primary outcomes
• Proportion of participants who received a blood transfusion
Secondary outcomes
• Amount of blood transfused per participant (units)
• Postoperative mortality in the short term (within 30 days) and
long term (from 31 days up to one year)
• Postoperative morbidity (including infection and adverse
events within 30 days)
• Any validated measure of quality of life (within 30 days)
• Measurement of the following haematologic parameters:
haemoglobin, haematocrit, ferritin level and reticulocyte count,
measured as continuous variables at predetermined time
points: pretreatment; preoperatively but post-treatment; and
postoperatively.
Information size calculation for the primary outcome
Assuming that 20% of participants in the control group will require
a blood transfusion, and that there is a treatment effect of 30% (i.e.
14% require transfusion following iron therapy), 819 people need
to be randomised to receive either iron therapy or control in order
to obtain a reliable estimate of the treatment effect (alpha = 0.05,
beta = 0.1) (Keeler 2015).
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Search methods for identification of studies
In order to reduce publication and retrieval biases we did not re-
strict our search by language, date or publication status.
Electronic searches
An updated search was run on 30 July 2018, and the results of this
have been fully incorporated into the review:
• Cochrane Injuries Group Specialised Register (30 July 2018);
• Cochrane Central Register of Controlled Trials (CENTRAL; the
Cochrane Library Issue 10, 2018);
• Ovid MEDLINE(R), Ovid MEDLINE(R) In-Process & Other
Non-Indexed Citations, Ovid MEDLINE(R) Daily and Ovid
OLDMEDLINE(R) (1946 to 30 July 2018);
• Embase Classic and Embase (Ovid SP) (1947 to 30 July 2018);
• PubMed (30 July 2018);
• ISI Web of Science: Science Citation Index Expanded (SCI-EX-
PANDED) (1970 to 30 July 2018);
• ISI Web of Science: Conference Proceedings Citation In-
dex-Science (CPCI-S) (1990 to 30 July 2018);
• ClinicalTrials.gov (clinicaltrials.gov) (30 July 2018);
• WHO International Clinical Trials Registry Platform (ICTRP)
Search Portal (apps.who.int/trialsearch) (30 July 2018).
All 30 July 2018 search strategies are listed in Appendix 1. We adapt-
ed the MEDLINE search strategy as necessary for each of the other
databases: the added study filter is a modified version of the Ovid
MEDLINE Cochrane Highly Sensitive Search Strategy for identify-
ing randomised trials; to the Embase search strategy we added the
study design terms as used by the UK Cochrane Centre (Lefebvre
2011).
On 28 November 2019, the Cochrane Injuries Group's Information
Specialist ran a top-up search of these databases, the searches are
listed in Appendix 2; one study is now awaiting classification.
Searching other resources
We did not search any other resources.
Data collection and analysis
The Cochrane Injuries Group's Information Specialist ran the July
2018 searches and collated the search results before passing them
on to two review authors (ON and BK) for screening. The results of
the November 2018 top-up searches were given an initial screening
by the Information Specialist before being passed to the review au-
thors for further examination.
Selection of studies
Two review authors (ON and BK) examined the citations indepen-
dently and applied pre-agreed selection criteria to identify all po-
tentially eligible studies. Both review authors reviewed the full text
of all randomised trials that used iron therapy in surgery. There
were no disagreements between authors. We describe the charac-
teristics of excluded studies and reasons for their exclusion in the
'Characteristics of excluded studies' table.
Data extraction and management
Independently, two review authors (ON and BK) extracted data rel-
evant to each included study using a standardised data extraction
form, and presented information about the studies in the 'Charac-
teristics of included studies' table. Both BK and another review au-
thor (HA) independently double-checked the data. There were no
disagreements between the review authors. BK, ON, JS, MB and AA
are authors of one of the included trials, Keeler 2017. AM indepen-
dently extracted data from Keeler 2017 to avoid bias. In addition,
the Cochrane Funding Arbiter's panel recommended that a new,
unconflicted review author should repeat the data extraction and
assessment of risk of bias. This author, HA, independently checked
all data extraction, 'Risk of bias' tables and conclusions, including
Keeler 2017, to ensure there was no serious bias in the review find-
ings.
Assessment of risk of bias in included studies
Two review authors (ON and BK) independently assessed each
study report for risk of bias by making judgements on the following
questions according to the criteria outlined in the Cochrane Hand-
book for Systematic Reviews of Interventions (Higgins 2011). A third
review author (HA) independently assessed risk of bias to ensure
agreement.
• Was the allocation sequence adequately generated (to check for
possible selection bias)?
• Was the allocation sequence adequately concealed (to check for
possible selection bias)?
• Was the study blinded with reference to participants, person-
nel and outcome assessors (to check for possible performance
bias)?
• Was there a suggestion of incomplete outcome data (to check
for possible attrition bias through withdrawals, dropouts and
protocol deviations)?
• Was there any suggestion of selective outcome reporting?
• Were there any other sources of bias?
We assessed the magnitude and direction of bias based upon our
assessment of each study. If we considered bias likely to impact on
findings, we planned to explore the effect of the potential bias by
undertaking sensitivity analyses, however, this was not possible,
due to lack of data.
A summary of our decisions about different domains of bias is
shown in Figure 1 and Figure 2.
 
Iron therapy for preoperative anaemia (Review)









Cochrane Database of Systematic Reviews
Figure 1.   Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages
across all included studies. Six studies are included in this review.
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Figure 2.   Risk of bias summary: review authors' judgements about each risk of bias item for each included study.
 
Measures of treatment e?ect
For dichotomous data, we present results as summary risk ratios
(RRs) with 95% confidence intervals (CIs).
For continuous data we calculated mean differences (MDs) with
95% CIs between the study groups.
The amount of blood transfused per participant was measured in
units (where one unit contains approximately 250 mL of blood).
Unit of analysis issues
The unit of analysis was the participant. For cross-over studies we
decided we would include data from the first period before the
cross-over only, due to challenges with defining a wash-out period
of suitably long duration.
Dealing with missing data
For included studies, we noted the levels of attrition in the 'Risk of
bias' tables. We carried out analyses on an intention-to-treat basis
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as far as possible. We emailed trial authors for missing data, but
received no responses.
Assessment of heterogeneity
We assessed included trials for heterogeneity by examining forest
plots visually for estimated treatment effects. We used the I2 statis-
tic to assess statistical heterogeneity. We regarded heterogeneity
as moderate when I2 was greater than 30%.
Assessment of reporting biases
We assessed included trials for reporting bias based upon the ab-
sence of main outcomes expected for trials of iron therapy, name-
ly blood transfusion, and levels of haemoglobin and ferritin. Where
practicable, we compared the a priori research protocol with the
published report.
Data synthesis
We carried out statistical analysis using the Cochrane software, Re-
view Manager 2014. We used a fixed-effect model in the meta-analy-
sis and the Mantel-Haenszel test for statistical significance.
We present outcome data in tables and as forest plots. We interpret-
ed our findings using the GRADE approach and created 'Summary
of findings' tables using GRADE Profiler (GRADEpro GDT), according
to guidance in the Cochrane Handbook for Systematic Reviews of In-
terventions (Higgins 2011). We compared measurements taken at
final follow-up between treatment groups.
In the 'Summary of findings' tables, we report the main study out-
comes with the data available. These include the number of partic-
ipants who received a blood transfusion, quality of life, haemoglo-
bin levels at the end of preoperative treatment (g/dL), haemoglo-
bin levels postoperatively (g/dL) and ferritin levels (ng/mL).
Subgroup analysis and investigation of heterogeneity
In future updates of this review, if we identify heterogeneity (I2 >
30%), we will investigate it using subgroup analysis and sensitivity
analysis. We plan to carry out the following subgroup analyses:
• variations in interventions (e.g. dosing, time period of interven-
tion, formulation of iron);
• different types of operations;
• different patient populations;
• different control groups (placebo, no treatment, or standard
practices).
Sensitivity analysis
In future updates of this review, if data permit, we will conduct sen-
sitivity analysis based on allocation concealment (low risk of bias
versus unclear or high risk of bias), and may also explore the impact
of including studies with high levels of missing data.
R E S U L T S
Description of studies
Results of the search
Combined searches to 30 July 2018
When the original search for the 2015 review (894 records) was com-
bined with the 2016 (1369 records) and 2018 search (1763 records)
for this update, a total of 4026 records was retrieved. After re-
moval of duplicates, the 2015 search yielded 894 records, the 2016
search yielded a further 354 records, and the 2018 search another
89 records, making a total of 1337 records from these three search-
es. We identified one additional article from an internet search
(Metha 2015), which brought the total to 1338 records. We discard-
ed 1319 of the records, as the studies they described did not meet
the criteria for inclusion. We assessed the full text of the 19 remain-
ing articles for eligibility; we discarded four articles that concerned
two ongoing studies (see Characteristics of ongoing studies), and
excluded four articles that reported four studies that did not meet
our inclusion criteria (see Excluded studies). We included the re-
maining 11 articles (relating to six studies) in the review as these in-
vestigated iron therapy as an intervention without the concomitant
administration of another therapy (Edwards 2009; Froessler 2016;
Keeler 2017; Kim 2009; Lidder 2007; Serrano-Trenas 2011), see Fig-
ure 3.
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Figure 3.   Study flow diagram for combined searches to 30 July 2018 (fully incorporated into review)
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Figure 3.   (Continued)
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28 November 2019 search
The 2019 top-up search yielded 335 records; after deduplication
242 records remained. These will be examined thoroughly and the
results incorporated in the next update of this review. Screening
thus far has indicated that 122 records are not relevant, while 116
are worthy of further consideration. Two are additional papers for
a study that is already included in the review (Keeler 2017); one has
been added to the study references, and reference details for the
other - a correction - have been appended to those of the relevant
paper, thus bringing the total number of references relating to the
six included trials to 12. The remaining two records refer to a study
that is awaiting classification (Padmanabhan 2019), see Figure 4.
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Figure 4.   Study flow diagram for 28 November 2019 top-up searches (not completely incorporated into review)
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Figure 4.   (Continued)
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Included studies
We found 12 articles relating to six randomised controlled trials
(RCTs), with a total of 372 participants, that evaluated the use of
preoperative iron therapy to correct anaemia. Four studies were
prospectively registered in a clinical trial registry (Edwards 2009;
Froessler 2016; Keeler 2017; Serrano-Trenas 2011), and the two old-
er studies do not appear to have been registered (Kim 2009; Lidder
2007).
Participants
Three studies were in colorectal surgery (Edwards 2009; Keeler
2017; Lidder 2007), one in gynaecological surgery (Kim 2009), one
in orthopaedic surgery (Serrano-Trenas 2011), and one in major ab-
dominal surgery (Froessler 2016).
Interventions
All six studies detailed the use of iron therapy prior to surgery for
preoperative anaemia. One study compared oral iron versus no iron
therapy (Lidder 2007), three studies compared intravenous iron
versus placebo or usual care (Edwards 2009; Froessler 2016; Serra-
no-Trenas 2011), and two studies compared intravenous iron ver-
sus oral iron (Keeler 2017; Kim 2009).
Interventions and comparisons were either oral or intravenous iron
compared to each other or to standard care with or without place-
bo. Lidder 2007 conducted an open-label, prospective RCT that
compared oral ferrous sulphate with no iron therapy. Edwards 2009
compared 600 mg intravenous iron sucrose against placebo a min-
imum of two weeks before surgery in a prospective, blinded, place-
bo-controlled randomised trial. Kim 2009 administered either in-
travenous iron sucrose or oral iron (80 mg/day iron succinylate)
in the three weeks preceding surgery. Serrano-Trenas 2011 con-
ducted a prospective RCT that compared standard treatment with
600 mg intravenous iron sucrose. Froessler 2016 gave participants
either intravenous ferric carboxymaltose or usual care. Uniquely,
in this trial, a preoperative and postoperative dose of intravenous
iron were administered; the second postoperatively if blood loss
exceeded 100 mL. Keeler 2017 randomised participants to receive
either oral ferrous sulphate 200 mg twice a day or intravenous fer-
ric carboxymaltose with dose based upon haemoglobin level and
weight.
Outcomes
All studies except Kim 2009 reported the primary outcome of blood
transfusion. Studies also reported levels of haemoglobin and fer-
ritin, and morbidity. Froessler 2016 and Keeler 2017 reported qual-
ity of life, but the Keeler 2017 study authors did not report these
data in time for publication of the present version of this review.
Excluded studies
We excluded four articles relating to four studies: Metha 2015 was
excluded because this study was not prospectively registered and
was published after 2010. One other study excluded anaemic par-
ticipants (Garrido-Martin 2012), while a second had no subgroup
analysis of anaemic participants (Andrews 1997). The fourth study
randomised only non-anaemic participants, and gave all anaemic
participants iron (Crosby 1994). We also identified four articles re-
lating to two ongoing studies which currently have no available da-
ta (NCT01692418; NCT02632760), so could not be included in this
iteration of the review.
Risk of bias in included studies
A summary of the review authors' 'Risk of bias' judgements can be
found in Figure 1 and Figure 2.
Allocation
All included studies except Lidder 2007 reported allocation using
a computer-generated randomisation sequence, so we considered
them to be at a low risk of bias for this domain. The method of ran-
dom sequence allocation was not clearly described in Lidder 2007,
so we judged this study to be at an unclear risk of bias for this do-
main.
We judged all studies except Lidder 2007 and Serrano-Trenas 2011
to be at a low risk of bias for allocation concealment with study
methodology describing clear methods for preventing investiga-
tors knowledge of assignment (opaque sealed envelopes, investi-
gator blinding), but we considered Lidder 2007 and Serrano-Trenas
2011 to be at an uncertain risk of bias for allocation concealment,
as they did not detail how allocation concealment was achieved.
Blinding
Performance bias
One study was placebo-controlled with participants blinded to in-
tervention by means of an opaque sheath over the intravenous giv-
ing set and assessed as being at low risk of bias (Edwards 2009). All
other trials were unblinded with either different routes of admin-
istration (Keeler 2017; Kim 2009), or compared to usual care and
were assessed as being at unclear risk of bias (Froessler 2016; Lid-
der 2007; Serrano-Trenas 2011).
Detection bias
The absence of blinding is less likely to create bias in objective out-
come measures, such as changes in haemoglobin and ferritin lev-
els, but could influence subjective assessments, such as quality of
life questionnaires; only one study reported quality of life in time
to be used in the review, and we assessed it as being at unclear
of risk of bias (Froessler 2016). Blood transfusion, unless adminis-
tered under a strict transfusion protocol, could potentially be in-
fluenced by lack of blinding in these studies. Four studies report-
ed that the clinicians treating participants were blinded to the in-
tervention the participant received and we assessed these as being
at low risk of bias (Edwards 2009; Keeler 2017; Lidder 2007; Serra-
no-Trenas 2011). One study did not report whether clinicians were
blinded (Kim 2009), and therefore we assessed it as being at unclear
risk of bias.
Incomplete outcome data
One study excluded participants with a compliance of less than
80% from the analysis, instead of completing analysis on an inten-
tion-to-treat basis, and we considered it to have a high risk of bias
(Kim 2009). This is important, especially when considering oral iron
therapy, where compliance could be a major factor in the efficacy
of the treatment.
One study did not report whether data were analysed on an inten-
tion-to-treat basis (Lidder 2007), and we assessed it as being at un-
clear risk of bias. All other studies included all patient data from
participants in their analyses and we assessed them as being at
low risk of bias (Froessler 2016; Keeler 2017; Edwards 2009; Serra-
no-Trenas 2011).
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Selective reporting
After comparison of the study register record with the published
study reports, we found no evidence of selective reporting in four
of the studies included in this review and assessed their risk of bias
for this domain as low (Froessler 2016; Keeler 2017; Kim 2009; Lid-
der 2007). Two studies were not prospectively registered and we
assessed them as being at unclear risk for reporting bias (Edwards
2009; Serrano-Trenas 2011).
Other potential sources of bias
One study reported early termination of the study after investiga-
tors reported the number of blood transfusions was higher than ex-
pected (Froessler 2016). Three independent assessors evaluated in-
terim data and two advised termination due to higher than expect-
ed levels of poor outcomes. This interim analysis was conducted in-
dependently of the investigators and the data were blinded. How-
ever, the risk of bias is unclear. We judged the risk of bias for this
domain to be low for all the other studies.
E?ects of interventions
See: Summary of findings for the main comparison Iron thera-
py compared to placebo, no treatment or standard care for preop-
erative anaemia; Summary of findings 2 Intravenous iron therapy
compared to oral iron therapy for preoperative anaemia
Comparison 1: iron therapy compared to placebo, no
treatment or standard care
Primary outcome: proportion of participants who received a
blood transfusion
Four studies measured and reported the proportion of partici-
pants who received allogeneic blood transfusions (Edwards 2009;
Froessler 2016; Lidder 2007; Serrano-Trenas 2011). Iron therapy
produced no clear reduction in the proportion of participants who
received a blood transfusion (risk ratio (RR) 1.21, 95% confidence
interval (CI) 0.87 to 1.70; I2 = 54%; 4 studies, 200 participants; mod-
erate-quality evidence; Analysis 1.1).
Secondary outcomes
Amount of blood transfused per participant (in units)
Four studies measured and reported the number of units of blood
transfused in each treatment group (Edwards 2009; Froessler 2016;
Lidder 2007; Serrano-Trenas 2011). However, it was not possible to
combine the data because they were skewed and one study did not
report subset data for the 90 participants who were anaemic at re-
cruitment (Serrano-Trenas 2011). The raw data are given in the ta-
ble below.
 
Study Control Iron group
Edwards 2009 Median 2 units (interquartile range (IQR) 3 units; n = 9;
unspecified number of total units transfused)
Median 0 units (IQR 1 unit; n = 9; unspecified number
of total units transfused)
Froessler 2016 Median 0 units (range 0 to 2 units) Median 0 units (range 0 to 5 units)
Lidder 2007 Median 2.5 units (range 0 to 11 units; n = 14; 39 units
transfused in total)




Mean 0.87 units (standard deviation (SD) 1.21 units; n =
100 (50 anaemic))
Mean 0.76 units (SD 1.16 units; n = 100 (40 anaemic))
 
Postoperative mortality in the short term (within 30 days) and long
term (from 31 days up to one year)
Two studies did not measure or report mortality (38 participants)
(Edwards 2009; Lidder 2007). Two studies measured and report-
ed no clear difference in short-term mortality (162 participants)
(Froessler 2016; Serrano-Trenas 2011). In the former study, one
death occurred in the intervention group and none in the control;
in the latter, 10 participants died in the intervention arm and 11 in
the control. As the former study was terminated early, the time pe-
riods for these data may not be not directly comparable. No studies
measured or reported long-term mortality.
Postoperative morbidity (including infections and adverse events)
Two studies did not measure or report postoperative morbidity
(38 participants) (Edwards 2009; Lidder 2007). Two studies mea-
sured and reported no difference in morbidity (162 participants)
(Froessler 2016; Serrano-Trenas 2011). Froessler 2016 reported
three minor adverse events: headache, light-headedness and back
pain (72 participants). Serrano-Trenas 2011 also reported three mi-
nor adverse events: one skin rash and two participants with gener-
al discomfort (90 participants). No serious adverse events were re-
ported in any study.
Any validated measure of quality of life
Froessler 2016 reported no clear difference in quality of life scores
between groups four weeks after intervention (90 participants),
measured using the 36-item Short Form Survey (SF-36) (Analysis
1.2) (Ware 1992). The other studies within this comparison did not
measure quality of life.
Haematologic parameters measured pretreatment, preoperatively but
post-treatment, and postoperatively
Haemoglobin level
Both Lidder 2007 and Serrano-Trenas 2011 collected data on this
outcome at two time points, pretreatment and preoperatively
post-treatment, but the data were not reported separately for the
anaemic participants.
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Edwards 2009 and Froessler 2016 reported haemoglobin levels for
the 83 anaemic participants at the end of preoperative treatment,
when there was no difference in haemoglobin levels between the
control and intervention groups (mean difference (MD) 0.63 g/dL,
95% CI -0.07 to 1.34; I2 = 41%; 2 studies, 83 participants; low-quality
evidence; Analysis 1.3).
Postoperatively, there was no clear difference between haemoglo-
bin levels in the two groups (MD 0.17 g/dL, 95% CI -0.29 to 0.63; I2 =
78%; 2 studies, 86 participants; low-quality evidence; Analysis 1.4).
Haematocrit level
The Edwards 2009 study collected data on haematocrit levels pre-
treatment, at the end of treatment preoperatively, and after treat-
ment postoperatively, but no standard deviation values were re-
ported and so it was not possible to analyse the data.
Ferritin level
The Lidder 2007 and Serrano-Trenas 2011 studies did not report fer-
ritin data separately for anaemic participants.
The Edwards 2009 study collected data on ferritin levels pretreat-
ment, at the end of treatment preoperatively, and after treatment
postoperatively, but no standard deviation values were reported
and so it was not possible to analyse the data.
Only Froessler 2016 reported an increase in ferritin at four weeks
with intravenous iron therapy (MD 149.00, 95% CI 25.84 to 272.16; 1
study, 63 participants; Analysis 1.5). This is clinically important ev-
idence of iron repletion.
Reticulocyte count
The Lidder 2007 study authors performed reticulocyte counts at
two time points, pretreatment and preoperatively post-treatment,
but the data were not reported separately for the 20 anaemic par-
ticipants. The Edwards 2009, Serrano-Trenas 2011 and Froessler
2016 studies did not report reticulocyte count.
Comparison 2: intravenous iron therapy compared to oral iron
therapy
Two studies compared intravenous iron therapy to oral iron thera-
py, Kim 2009 and Keeler 2017 (172 participants).
Primary outcome: proportion of participants who received a
blood transfusion
The Kim 2009 study did not measure this outcome. The Keeler 2017
study (116 participants) reported no difference in blood transfu-
sions between the oral and intravenous iron groups overall (Analy-
sis 2.1).
Secondary outcomes
Amount of blood transfused per participant (in units)
The Kim 2009 study did not measure this outcome. Keeler 2017 (116
participants) reported no difference in the amount of blood trans-
fused (Analysis 2.2).
Postoperative mortality in the short term (within 30 days) and long
term (from 31 days up to one year)
The Kim 2009 study did not measure mortality. Keeler 2017 (116
participants) did not report 30-day mortality, but did report 90-day
mortality, for which there was no clear difference between the in-
tervention groups (six deaths in the oral iron group, eight in the in-
travenous group).
Postoperative morbidity (including infections and adverse events)
There was no difference in the grade or risk of all complications, or
infective complications, between interventions in the Keeler 2017
study (116 participants).
The Kim 2009 study reported no severe adverse events, though mi-
nor adverse events were observed in each group. These included
two cases of myalgia and one case of injection pain in the intra-
venous iron group, and one report of nausea and one of dyspepsia
in the oral iron group (56 participants).
Keeler 2017 reported one serious adverse event, which was a rash
that followed administration of intravenous iron, which was treat-
ed with an oral antihistamine. Minor adverse events were observed
in both groups, most commonly headaches in the intravenous iron
group, and two participants experienced dyspepsia and constipa-
tion in the oral iron group (116 participants).
Any validated measure of quality of life
The Kim 2009 study did not measure this outcome. The Keeler 2017
study authors did measure quality of life but the data were not re-
ported in time for publication of the present version of this review.
Haematologic parameters measured pretreatment, preoperatively but
post-treatment, and postoperatively
Haemoglobin level
The Kim 2009 and Keeler 2017 studies reported haemoglobin levels
pretreatment, when there was no difference between the control
and intervention groups.
Both the Kim 2009 and Keeler 2017 studies measured haemoglo-
bin levels preoperatively post-treatment. Haemoglobin levels were
higher in the intravenous iron therapy group than the oral iron ther-
apy group (MD 1.23 g/dL, 95% CI 0.80 to 1.65; I2 = 79%; 2 studies,
172 participants; low-quality evidence; Analysis 2.3).
These results are despite Kim 2009 only analysing those partici-
pants with more than 80% compliance with oral iron therapy, and
higher than expected compliance with oral iron therapy seen in the
Keeler 2017 study.
Haematocrit level
The Kim 2009 and Keeler 2017 studies did not measure this out-
come.
Ferritin level
The Kim 2009 and Keeler 2017 studies reported ferritin levels pre-
treatment, and there was no difference between the control and in-
tervention groups (MD 6.59 ng/mL, 95% CI -11.75 to 24.93; I2 = 20%;
2 studies, 151 participants; Analysis 2.4). The results from these
studies have wide standard deviations as a result of small sample
sizes and very large differences in ferritin levels that ranged from
under 30 ng/mL for iron deficiency to over 1000 ng/mL in partici-
pants who were iron replete.
The Kim 2009 and Keeler 2017 studies reported ferritin levels pre-
operatively post-treatment. Ferritin levels were higher in the intra-
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venous iron therapy group than the oral iron therapy group (MD
395.03 ng/mL, 95% CI 227.72 to 562.35; I2 = 69%; 2 studies, 151 par-
ticipants; low-quality evidence; Analysis 2.5).
Reticulocyte count
The Kim 2009 and Keeler 2017 studies did not measure this out-
come.
D I S C U S S I O N
Summary of main results
We identified six prospective, randomised controlled trials (RCTs),
involving a total of 372 participants, that evaluated preoperative
iron therapy to correct anaemia. Three studies were in colorectal
surgery (Edwards 2009; Keeler 2017; Lidder 2007), one in gynae-
cological surgery (Kim 2009), one in orthopaedic surgery (Serra-
no-Trenas 2011), and one in major abdominal surgery (Froessler
2016). Five trials reported the primary outcome (proportion of par-
ticipants who received allogeneic blood transfusions) for 316 peo-
ple (200 iron versus standard care or placebo, 116 oral iron ver-
sus intravenous iron). Meta-analysis of iron therapy versus place-
bo, no treatment or standard care showed no reduction in the pro-
portion of participants who received a blood transfusion (risk ra-
tio (RR) 1.21, 95% confidence interval (CI) 0.87 to 1.70; I2 = 54%; 4
studies, 200 participants; moderate-quality evidence; Analysis 1.1).
Only one study reported transfusion after oral iron or intravenous
iron and reported no difference in transfusions (Keeler 2017). The
total number of participants is far smaller than the 891 participants
our information size calculation indicated would be necessary to
detect a difference.
For the secondary outcomes, Edwards 2009, Kim 2009, Keeler 2017
and Froessler 2016 reported change in haemoglobin level for the
anaemic participants specifically. No clear difference in haemoglo-
bin at the end of preoperative treatment was seen with iron therapy
compared to placebo or standard care (mean difference (MD) 0.63
g/dL, 95% CI -0.07 to 1.34; I2= 41%; 2 studies, 83 participants; low-
quality evidence; Analysis 1.3). There was an increase in haemoglo-
bin with intravenous iron at the end of treatment preoperatively
(MD 1.23 g/dL, 95% CI 0.80 to 1.65; I2 = 79%; 2 studies, 172 partici-
pants; low-quality evidence; Analysis 2.3), however, the Kim 2009
study authors possibly biased their results through the exclusion of
participants who had a less than 80% compliance with treatment.
Ferritin levels were increased by intravenous iron, both when com-
pared to standard care (Froessler 2016), and compared to oral iron
(MD 395.03 ng/mL, 95% CI 227.72 to 562.35; I2 = 69%; 2 studies, 151
participants; low-quality evidence; Analysis 2.5; Keeler 2017; Kim
2009).
Other secondary outcomes including quality of life, short-term
mortality and postoperative morbidity were not measured or re-
ported in most studies, and where they were there were no clear
differences between interventions.
Overall completeness and applicability of evidence
Evidence regarding iron therapy for preoperative anaemia is lim-
ited currently, with data available only from six RCTs, three of
which had very small sample sizes. Furthermore, the 372 partici-
pants available for analysis of the primary outcome constitute only
45% of the 819 participants recommended by the information size
calculation, which prevents us from reaching reliable conclusions
regarding the effects of iron therapy given preoperatively. These
studies are also limited in their generalisability, as only three surgi-
cal specialities are represented, albeit specialities where anaemia
and blood loss are common. Thus far, no studies have examined
cost-effectiveness.
Two ongoing studies in major open abdominal surgery, the PRE-
VENTT trial (500 participants), and in cardiac surgery, the ITACS trial
(1000 participants), will substantially increase the amount of avail-
able data to analyse, and will include data on safety, e.g. risk of in-
fections, quality of life and cost-effectiveness.
Quality of the evidence
This update from the previous Cochrane Review, Ng 2015b, has
doubled the number of included studies from three to six, and in-
creased the number of participants from 114 to 372. The three more
recent studies have been larger and better designed, and report-
ed morbidity and mortality fully, and two reported quality of life
(though results from Keeler 2017 were not reported in time for pub-
lication of the present version of this review). However, the total of
372 participants in our analysis falls far short of the 819 required
by our information size calculation to detect a 30% reduction in
blood transfusions. The GRADE assessment of quality for the pri-
mary outcome measure, proportion of participants who needed a
blood transfusion, was moderate quality due to low numbers of
participants. We assessed all other outcomes as low quality due
to small numbers of participants and the exclusion of non-compli-
ant participants in one trial (Kim 2009). In addition, the Kim 2009
study made important omissions by not recording blood transfu-
sions and quality of life outcomes. It also excluded data in the final
analysis from participants whose compliance was less than 80%,
acknowledging that compliance is a major factor in the efficacy of
oral iron therapy, but, therefore, not reflecting the reality that many
patients do not adhere to oral iron because of side effects.
Edwards 2009, Lidder 2007 and Serrano-Trenas 2011 did not ex-
clude non-anaemic participants, or assess for iron deficiency. While
they included a subgroup analysis of anaemic participants, they did
not report all data for this anaemic group, and these studies were
not powered to show a difference in the group of participants that
might require iron to correct their anaemia, namely those with iron
deficiency anaemia. As a result these studies have even fewer par-
ticipants with which to determine the true effect of iron therapy.
Potential biases in the review process
BK, ON, JS, MB and AA are authors of one of the included trials,
Keeler 2017. AM independently extracted data from Keeler 2017 be-
cause he was not involved with the study. The Cochrane Funding Ar-
biter's panel recommended that a new, unconflicted author should
repeat the data extraction and assessment of risk of bias. This au-
thor, HA, independently checked all data extraction, 'Risk of bias'
tables and conclusions, including Keeler 2017, to ensure the data
had been extracted and reported accurately.
Agreements and disagreements with other studies or
reviews
The six RCTs presented here fail to support the conclusions of ob-
servational and case-control studies that have demonstrated that
iron therapy reduces allogeneic blood transfusion and improves
preoperative haemoglobin levels. These include studies from col-
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orectal surgery (Okuyama 2005; Quinn 2010), orthopaedics (Cuen-
ca 2004; Cuenca 2005; Munoz 2014; Theusinger 2007), and gynaeco-
logical surgery (Breymann 2008). These findings also contradict the
findings of a much larger and broader systematic review of 72 stud-
ies that included 10,605 participants and examined anaemia more
generally, including conditions other than preoperative anaemia
(Litton 2013). In the Litton 2013 review, meta-analysis showed in-
travenous iron to be associated with an increase in haemoglobin
(standard MD 6.5 g/L, 95% CI 5.1 g/L to 7.9 g/L) and a reduced risk of
blood transfusion (RR 0.74, 95% CI 0.62 to 0.88). Our results howev-
er, may be a reflection of the small sample sizes in the six included
studies and the ability to detect a difference with so few data.
A U T H O R S '   C O N C L U S I O N S
Implications for practice
Preoperative anaemia is associated with fatigue, poorer quality of
life, increased blood transfusions and an increased risk of post-
operative morbidity and mortality. The most common cause of
anaemia is iron deficiency. Based on the current evidence we can-
not conclude that iron therapy improves preoperative anaemia, or
reduces the number of patients who receive allogeneic blood trans-
fusions as a result of surgery.
The results for intravenous iron therapy are consistent with a
greater increase in haemoglobin and ferritin levels when compared
to oral iron, but provide low-quality evidence. However, these con-
clusions are based on six studies with a total number of participants
well below the number we calculate is required to be conclusive.
Further research is very likely to change the results.
Implications for research
Higher quality studies are required to determine the efficacy of iron
therapy for the treatment of preoperative anaemia. Ideally these
should be adequately powered, large, multicentre trials across sur-
gical specialities. They should report data for anaemic patients sep-
arately or, ideally, include only anaemic patients. They should as-
sess for aetiology of the anaemia treated, including anaemia of
chronic disease and true iron deficiency anaemia. Outcome mea-
surements should include some measure of quality of life, postop-
erative complications, and morbidity and mortality, in addition to
the haematological parameters and frequency of allogeneic blood
transfusion reported in most current studies. Researchers should
include information about side effects and harms from the inter-
vention. It will be important for these studies to include strict trans-
fusion guidelines and definitions of iron deficiency and anaemia,
such as those defined in the international consensus statement on
perioperative anaemia and iron deficiency (Munoz 2017).
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C H A R A C T E R I S T I C S   O F   S T U D I E S
Characteristics of included studies [ordered by study ID]
 
Methods Blinded, randomised, placebo-controlled trial
Participants Preoperative patients undergoing surgery for colorectal cancer (n = 60; note only 18 participants were
anaemic)
Interventions Iron therapy group: 2 doses of IV iron sucrose 300 mg in 250 mL 0.9% saline (total 600 mg), a minimum
of 2 weeks before surgery
Edwards 2009 
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Control group: 2 doses of 250 mL IV placebo (0.9% saline)
Outcomes Transfusion rates
Amount of blood transfused
Recruitment and admission haemoglobin
Notes Study had only 9 anaemic participants in each arm.
Authors were contacted by email for subanalysis data but did not respond.
This study was prospectively registered through the UK Medicines and Healthcare products Regulatory
Agency; EU Clinical Trial Registration Number: 2005-003608-13 UK
Ethical Committee Approval was granted from the Cornwall and Plymouth Research Ethics Committee
on 26 August 2005.
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Quote: "allocated to either the treatment (iron) group or a placebo group,
based on a computer-generated randomisation sequence provided by the Re-
search and Development Support Unit. To ensure equal numbers of anaemic
patients in each treatment group, randomisation was stratified according to
pre-recruitment Hb status: normal (Hb level at least 13.5 g/dL in males and
12.5 g/dL in females), anaemic, or unknown (no test within 2 months of re-
cruitment). Block randomisation was used to ensure similar numbers in each
group for each subset."
Allocation concealment
(selection bias)
Low risk Quote: "Allocation codes were sealed in sequentially numbered opaque en-






Low risk Quote: "Although the investigator administering the infusion was not blind-
ed to the treatment group, this was concealed from the patient by using an
opaque sheath to cover the drug-giving set."
Blinding of outcome as-
sessment (detection bias) 
All outcomes
Low risk Quote: "The chief investigator and clinicians involved in perioperative care al-








Unclear risk Comment: none identified




Methods Randomised controlled trial of IV iron versus control (usual care)
Froessler 2016 
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Participants Adult participants with a ferritin level < 300 µg/L, transferrin saturation < 25% and haemoglobin < 120
g/L in women and < 130 g/L in men undergoing major abdominal surgery (n = 72)
Interventions Iron therapy group: single-dose IV ferric carboxymaltose 1000 mg or a maximum of 15 mg/kg preop-
eratively (median 8 days before surgery) with a second dose postoperatively of 50 mg per 100 mL of
blood loss
Control group: usual care
Outcomes Primary outcome: allogenic blood transfusion
Secondary outcomes: haemoglobin, ICU admission, perioperative morbidity, mortality, length of stay,
iron status and quality of life (SF36)
Notes Study was stopped early after interim data analysis showed high rates of red blood cell transfusion.
Quote: "The protocol was approved by the study hospital's human research ethics committee and reg-
istered with the Australian New Zealand Clinical Trials Registry (ACTRN12611000387921)." p. 42
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Quote: "Randomization followed a computer-generated number sequence
and allocation was conducted by telephone." p. 42
Allocation concealment
(selection bias)
Low risk Quote: "The surgeon performing the operation was informed of patient partic-





Unclear risk Quote: "The surgeon performing the operation was informed of patient partic-
ipation in the study but group allocation was not revealed"
Comment: no blinding of participants reported and no placebo administered.
It is unclear whether this would influence blood transfusion administration,
and it would be unlikely to change haemoglobin levels, but could be a major
influence on quality of life scores.
Blinding of outcome as-
sessment (detection bias) 
All outcomes
Unclear risk Comment: no report of who collected outcome data and whether they were




Low risk Comment: none identified
Selective reporting (re-
porting bias)
Low risk Comment: none identified





Methods Randomised control trial of IV versus oral iron
Participants Adult participants with haemoglobin < 110 g/L in women and < 120 g/L in men undergoing elective
surgery for colorectal adenocarcinoma (n = 116)
Keeler 2017 
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Interventions Oral iron therapy group: preoperative oral ferrous sulphate 200 mg twice a day
IV iron therapy group: preoperative IV ferric carboxymaltose. The dose was calculated on body weight
and haemoglobin; a maximum dose of 1000 mg was administered per week and a maximum of 2000
mg during the trial. If participants required 2 doses, the second dose was administered at least 7 days
after the first. The median duration of iron therapy was 21 days in each group.
Outcomes Primary outcome: blood transfusions
Secondary outcomes: haemoglobin, transferrin, saturations and ferritin, quality of life
Notes Inclusion criteria did not include ferritin or transferrin saturations
ClinicalTrials.gov Identifier: NCT01701310, EU Clinical Trials Register Number: 2011-002185-21.
According to the EU Clinical Trials Register, ethical approval for the study was granted on 5 September
2011 and received regulatory approval from the Medicines and Healthcare products Regulatory Agency
on 15 September 2011.
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Quote: "Recruited patients were randomized in a 1:1 fashion via a web-based
system using variable block allocation, stratified by patient age and sex"
Allocation concealment
(selection bias)





Unclear risk Comment: open-label study with no blinding due to the different routes of
intervention administration and the "darkening of stool when ingesting oral
iron". It is unclear whether this would influence blood transfusion administra-
tion, but it would be unlikely to change other quantitative measures, such as
haemoglobin, ferritin or transferrin saturations.
Blinding of outcome as-
sessment (detection bias) 
All outcomes





Low risk Comment: 4 participants had their operations cancelled, 1 died during anaes-
thesia and one was deemed inoperable at laparotomy. Participants analysed
on an intention-to-treat basis.
Selective reporting (re-
porting bias)
Low risk Comment: none identified




Methods Open-label, randomised controlled trial
Participants Anaemic preoperative participants with menorrhagia who were due to undergo surgery (n = 76; note
only 56 participants with > 80% compliance are included in the analysis, Hb < 90 g/L)
Interventions Oral iron therapy group: preoperative oral iron succinylate (dose 80 mg per day for 3 weeks preceding
surgery)
Kim 2009 
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IV iron therapy group: preoperative IV iron sucrose (dose according to Ganzoni’s formula for cumula-
tive iron deficit) 3 times a week, beginning 3 weeks before surgery
Outcomes Recruitment and admission haemoglobin
Notes The study took place between December 2005 and January 2007.
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)




Low risk Quote: "Group allocation was determined by one of the authors not directly





Unclear risk Comment: open-label study, no blinding, but unlikely to influence the change
in haemoglobin
Blinding of outcome as-
sessment (detection bias) 
All outcomes
Unclear risk Comment: no blinding, objective measurement of haemoglobin unlikely to be




High risk Quote: "Participants who had > 80% compliance were included in the analy-
sis"
Comment: not analysed on intention-to-treat basis; this is important because
oral iron reportedly has poor tolerance, and therefore poor compliance.
Selective reporting (re-
porting bias)
Low risk Comment: none identified




Methods Open-label randomised controlled trial
Participants Preoperative patients undergoing surgery for colorectal cancer (n = 49; note only 20 participants
anaemic)
Interventions Iron therapy group: preoperative oral ferrous sulphate 200 mg three times a day for 2 weeks before
surgery
Control group: no iron therapy
Outcomes Transfusion rates and amount of blood transfused
Pretreatment and preoperative haemoglobin
Notes The trial included anaemic and non-anaemic participants. Data were presented for all participants, and
anaemic participants.
Lidder 2007 
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Quote: "The study received approval from the Plymouth Healthcare Trust Local Research Ethics Com-
mittee." p. 418
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk Comment: study did not explain how randomisation was achieved
Allocation concealment
(selection bias)





Unclear risk Quote: "The clinical team (surgeons, nurses, anaesthetists) were blinded to
treatment allocation. It was not possible to use a placebo and blind the pa-
tient, as oral iron alters stool colour." p. 419
Blinding of outcome as-
sessment (detection bias) 
All outcomes
Low risk Quote: "The collection of data was performed by a research fellow not in-




Unclear risk Quote: "Two patients from each group were deemed unsuitable for resective
surgery at
admission, two underwent stent insertion and two were referred to the pallia-
tive care team."
Comment: no incomplete outcome data were reported
Selective reporting (re-
porting bias)
Low risk Comment: none identified from the published report. No study protocol is
available for bias assessment.




Methods Open-label, randomised controlled trial
Participants Preoperative patients over 65 years of age undergoing hip fracture surgery (n = 200, 90 participants Hb
< 120 g/L at baseline)
Interventions Iron therapy group: preoperative IV iron sucrose 600 mg in 3 doses of 200 mg IV over 48 hours before
surgery
Control group: standard care
Outcomes Transfusion rates




Length of hospital stay
Serrano-Trenas 2011 
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Notes Quote: "This trial was funded by the Spanish Ministry of Health and Consumer Affairs, through the
Instituto de Salud Carlos III, under Protocol Code EC07/90842, as part of the Biomedical and Health
Science Research Promotion Programme for the implementation of noncommercial clinical research
projects using drugs intended for human use, within the framework of the National Plan for Scien-
tific Research, Development and Innovation (RI+D+I) for the period 2004-2007. Prior authorization
was obtained from the Spanish Agency for Medicines and Health Products, under EudraCT Number
2007-007044-10." p. 97
According to the EU Clinical Trials Register, ethical approval for the study was granted on 11 February
2008 and approval for the study was granted on 4 March 2008.
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Opaque sealed envelopes generated from a randomisation list in blocks of 10
Allocation concealment
(selection bias)
Unclear risk Quote: "neither the patient nor the investigator could know which group the





Unclear risk Quote: "Blinding procedures were not used in this trial"
Comment: unclear if lack of blinding would influence transfusion practice or
other outcomes, but unlikely to influence haemoglobin and haematinics
Blinding of outcome as-
sessment (detection bias) 
All outcomes




Low risk Comment: data analysed on intention-to-treat basis
Selective reporting (re-
porting bias)
Unclear risk Comment: none identified





ICU: intensive care unit
IV: intravascular
 
Characteristics of excluded studies [ordered by study ID]
 
Study Reason for exclusion
Andrews 1997 Not a randomised controlled trial. All anaemic participants given iron therapy with no control arm.
Non-anaemic participants were randomised, but since they did not have preoperative anaemia, we
excluded this study from the review.
Crosby 1994 Study included all participants, anaemic and non-anaemic, did not stratify results to allow analysis
of the subset of participants with preoperative anaemia and randomised only non-anaemic partici-
pants giving all anaemic participants iron.
Iron therapy for preoperative anaemia (Review)









Cochrane Database of Systematic Reviews
Study Reason for exclusion
Garrido-Martin 2012 Study specifically excluded people with previous anaemia, therefore no participants in this study
had preoperative anaemia.
Metha 2015 Study was not registered prospectively. In order to be eligible for inclusion in the review, all RCTs
taking place after 2010 must have been prospectively registered (Roberts 2015).
 
Characteristics of studies awaiting assessment [ordered by study ID]
 
Methods Randomised non-blinded, single centre pilot study
Participants Participants were scheduled for elective cardiac surgery, defined as coronary artery bypass graM
and/or open valve surgery, who were anaemic according to the WHO criteria (haemoglobin < 120 g/
L for women and < 130 g/L for men).
Exclusion criteria: deficiencies in B12 or folic acid; low haemoglobin attributable to haemoglo-
binopathy; participating in another trial; inability to provide written consent; recognised allergy or
other contraindications to IV iron or related products; already receiving IV iron treatment; evidence
of significant symptomatic anaemia that would normally require urgent transfusion at the time of
assessment; haemoglobin > 90 g/L (9.0 g/dL); blood transfusion between enrolment and admission
and pregnancy and/or breastfeeding
Interventions Oral iron therapy group: 200mg ferrous sulphate twice daily, for 3-8 weeks before elective cardiac
surgery
IV iron therapy group: ferric carboxymaltose therapy, with dose calculated using a fixed dosing
regimen, 3-8 weeks before elective cardiac surgery
Outcomes Primary outcome: change in haemoglobin concentration before and approximately 3 weeks after
iron therapy
Secondary outcomes:
• biomarkers of iron metabolism such as iron, ferritin, transferrin, C-reactive protein, total iron
binding capacity and erythropoietin on the day of recruitment and on the day of surgery
• transfusion requirements and postoperative complications (acute kidney injury, atrial fibrillation
and any infection, such as chest infection, surgical site infection and septicaemia)
• patient-related outcomes such as duration of in-hospital stay and quality of life measures, such
as those recorded using the modified Short Form-36 (SF-36) version 1 and EUROQOL-5D (EQ-5D)
questionnaires.
Notes "Although commercial funding was received for the study, Vifor did not contribute to the study de-




WHO: World Health Organization
 
Characteristics of ongoing studies [ordered by study ID]
 
Trial name or title PREVENTT
NCT01692418 
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Methods Phase III double-blind randomised controlled trial
Participants 500 patients with anaemia (haemoglobin < 120 g/L) undergoing major open abdominal surgery
Interventions IV ferric carboxymaltose (dose 1000 mg) compared with placebo 10-42 days before major open ab-
dominal surgery
Outcomes Primary outcome: blood transfusion
Secondary outcomes: postoperative recovery, length of hospital stay, health care utilisation and
cost analysis
Starting date January 2014
Contact information Toby Richards, MD FRCS University College, London, UK




Trial name or title Intravenous iron for treatment of anaemia before cardiac surgery (ITACS)
Methods Randomised double-blind, controlled phase IV trial
Participants 1000 patients with anaemia before elective cardiac surgery
Interventions Preoperative IV ferric carboxymaltose (dose 1000 mg) compared with placebo
Outcomes Primary outcome: days alive and out of hospital
Secondary outcomes: haemoglobin, ICU stay, hospital stay, survival, quality of life and cost-effec-
tiveness
Starting date 15 July 2016
Contact information Paul S Myles, MD Bayside Health, Melbourne, Victoria, Australia
Notes Estimated study completion date October 2020
NCT02632760 
Abbreviations




D A T A   A N D   A N A L Y S E S
 
Comparison 1.   Iron therapy versus placebo, no treatment or standard care





Statistical method Effect size
1 Proportion of participants who received
a blood transfusion
4 200 Risk Ratio (M-H, Fixed, 95% CI) 1.21 [0.87, 1.70]
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Statistical method Effect size
2 Quality of life (SF-36) 4 weeks postopera-
tively
1   Mean Difference (IV, Fixed, 95% CI) Totals not select-
ed
3 Haemoglobin levels preoperatively
postintervention (g/dL)
2 83 Mean Difference (IV, Fixed, 95% CI) 0.63 [-0.07, 1.34]
4 Haemoglobin levels postintervention
postoperatively (g/dL)
2 86 Mean Difference (IV, Fixed, 95% CI) 0.17 [-0.29, 0.63]




Analysis 1.1.   Comparison 1 Iron therapy versus placebo, no treatment or standard
care, Outcome 1 Proportion of participants who received a blood transfusion.
Study or subgroup Control Iron therapy Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Fixed, 95% CI   M-H, Fixed, 95% CI
Edwards 2009 5/9 2/9 5.7% 2.5[0.65,9.69]
Froessler 2016 10/32 5/40 12.67% 2.5[0.95,6.58]
Lidder 2007 10/14 3/6 11.97% 1.43[0.6,3.4]
Serrano-Trenas 2011 23/50 22/40 69.66% 0.84[0.55,1.26]
   
Total (95% CI) 105 95 100% 1.21[0.87,1.7]
Total events: 48 (Control), 32 (Iron therapy)  
Heterogeneity: Tau2=0; Chi2=6.52, df=3(P=0.09); I2=54.01%  
Test for overall effect: Z=1.13(P=0.26)  
Favours control 100.1 50.2 20.5 1 Favours iron therapy
 
 
Analysis 1.2.   Comparison 1 Iron therapy versus placebo, no treatment or
standard care, Outcome 2 Quality of life (SF-36) 4 weeks postoperatively.
Study or subgroup Iron therapy Control Mean Difference Mean Difference
  N Mean(SD) N Mean(SD) Fixed, 95% CI Fixed, 95% CI
Froessler 2016 40 96 (14) 32 90 (26) 6[-4,16]
Favours control 400200-400 -200 0 Favours iron therapy
 
 
Analysis 1.3.   Comparison 1 Iron therapy versus placebo, no treatment or standard
care, Outcome 3 Haemoglobin levels preoperatively postintervention (g/dL).
Study or subgroup Iron therapy Control Mean Difference Weight Mean Difference
  N Mean(SD) N Mean(SD) Fixed, 95% CI   Fixed, 95% CI
Edwards 2009 9 11.2 (2) 9 11.9 (2.6) 11.09% -0.7[-2.82,1.42]
Froessler 2016 36 11.5 (1.3) 29 10.7 (1.7) 88.91% 0.8[0.05,1.55]
Favours control 10.5-1 -0.5 0 Favours iron therapy
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Study or subgroup Iron therapy Control Mean Difference Weight Mean Difference
  N Mean(SD) N Mean(SD) Fixed, 95% CI   Fixed, 95% CI
   
Total *** 45   38   100% 0.63[-0.07,1.34]
Heterogeneity: Tau2=0; Chi2=1.7, df=1(P=0.19); I2=41.25%  
Test for overall effect: Z=1.76(P=0.08)  
Favours control 10.5-1 -0.5 0 Favours iron therapy
 
 
Analysis 1.4.   Comparison 1 Iron therapy versus placebo, no treatment or standard
care, Outcome 4 Haemoglobin levels postintervention postoperatively (g/dL).
Study or subgroup Control Iron therapy Mean Difference Weight Mean Difference
  N Mean(SD) N Mean(SD) Fixed, 95% CI   Fixed, 95% CI
Edwards 2009 9 10.7 (1.2) 9 9.6 (0.9) 22.7% 1.1[0.13,2.07]
Froessler 2016 31 10.2 (0.9) 37 10.3 (1.3) 77.3% -0.1[-0.63,0.43]
   
Total *** 40   46   100% 0.17[-0.29,0.63]
Heterogeneity: Tau2=0; Chi2=4.55, df=1(P=0.03); I2=78.04%  
Test for overall effect: Z=0.73(P=0.46)  
Favours control 21-2 -1 0 Favours iron therapy
 
 
Analysis 1.5.   Comparison 1 Iron therapy versus placebo, no treatment
or standard care, Outcome 5 Ferritin level post-treatment (ng/mL).
Study or subgroup Iron therapy Control Mean Difference Mean Difference
  N Mean(SD) N Mean(SD) Fixed, 95% CI Fixed, 95% CI
Froessler 2016 36 248 (328) 27 99 (161) 149[25.84,272.16]
Favours control 400200-400 -200 0 Favours iron therapy
 
 
Comparison 2.   Intravenous versus oral iron therapy





Statistical method Effect size
1 Number of participants who received a
blood transfusion
1   Risk Ratio (M-H, Fixed, 95% CI) Totals not selected
2 Number of units of red blood cells re-
ceived
1   Mean Difference (IV, Fixed, 95% CI) Totals not selected
3 Haemoglobin level preoperatively
postintervention (g/dL)
2 172 Mean Difference (IV, Fixed, 95% CI) 1.23 [0.80, 1.65]
4 Ferritin level pretreatment (ng/mL) 2 151 Mean Difference (IV, Fixed, 95% CI) 6.59 [-11.75, 24.93]
5 Ferritin level preoperatively postinter-
vention (ng/mL)
2 151 Mean Difference (IV, Fixed, 95% CI) 395.03 [227.72,
562.35]
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Analysis 2.1.   Comparison 2 Intravenous versus oral iron therapy,
Outcome 1 Number of participants who received a blood transfusion.
Study or subgroup Oral iron Intravenous iron Risk Ratio Risk Ratio
  n/N n/N M-H, Fixed, 95% CI M-H, Fixed, 95% CI
Keeler 2017 14/61 10/55 1.26[0.61,2.61]
Favours oral iron 50.2 20.5 1 Favours intravenous iron
 
 
Analysis 2.2.   Comparison 2 Intravenous versus oral iron
therapy, Outcome 2 Number of units of red blood cells received.
Study or subgroup Oral iron Intravenous iron Mean Difference Mean Difference
  N Mean(SD) N Mean(SD) Fixed, 95% CI Fixed, 95% CI
Keeler 2017 57 0.6 (1.4) 53 0.7 (2) -0.07[-0.71,0.58]
Favours oral iron 52.5-5 -2.5 0 Favours intravenous iron
 
 
Analysis 2.3.   Comparison 2 Intravenous versus oral iron therapy,
Outcome 3 Haemoglobin level preoperatively postintervention (g/dL).
Study or subgroup Intravenous iron Oral iron Mean Difference Weight Mean Difference
  N Mean(SD) N Mean(SD) Fixed, 95% CI   Fixed, 95% CI
Keeler 2017 55 11.9 (1.4) 61 11 (1.5) 66.73% 0.89[0.37,1.41]
Kim 2009 30 10.5 (1.4) 26 8.6 (1.4) 33.27% 1.9[1.16,2.64]
   
Total *** 85   87   100% 1.23[0.8,1.65]
Heterogeneity: Tau2=0; Chi2=4.84, df=1(P=0.03); I2=79.33%  
Test for overall effect: Z=5.67(P<0.0001)  
Favours oral iron 21-2 -1 0 Favours intravenous iron
 
 
Analysis 2.4.   Comparison 2 Intravenous versus oral iron therapy, Outcome 4 Ferritin level pretreatment (ng/mL).
Study or subgroup Intravenous iron Oral iron Mean Difference Weight Mean Difference
  N Mean(SD) N Mean(SD) Fixed, 95% CI   Fixed, 95% CI
Keeler 2017 55 26 (66.6) 61 21 (23.4) 97.75% 5[-13.55,23.55]
Kim 2009 19 81.7 (272.1) 16 5.9 (5) 2.25% 75.8[-46.57,198.17]
   
Total *** 74   77   100% 6.59[-11.75,24.93]
Heterogeneity: Tau2=0; Chi2=1.26, df=1(P=0.26); I2=20.44%  
Test for overall effect: Z=0.7(P=0.48)  
Favours oral iron 200100-200 -100 0 Favours intravenous iron
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Analysis 2.5.   Comparison 2 Intravenous versus oral iron therapy,
Outcome 5 Ferritin level preoperatively postintervention (ng/mL).
Study or subgroup Intravenous iron Oral iron Mean Difference Weight Mean Difference
  N Mean(SD) N Mean(SD) Fixed, 95% CI   Fixed, 95% CI
Keeler 2017 55 558 (844.1) 61 27.5 (41) 56.13% 530.5[307.18,753.82]
Kim 2009 19 231.4
(561.7)
16 9.7 (10.3) 43.87% 221.7[-30.92,474.32]
   
Total *** 74   77   100% 395.03[227.72,562.35]
Heterogeneity: Tau2=0; Chi2=3.22, df=1(P=0.07); I2=68.96%  
Test for overall effect: Z=4.63(P<0.0001)  
Favours oral iron 1000500-1000 -500 0 Favours intravenous iron
 
 
A P P E N D I C E S
Appendix 1. Search strategies for 30 July 2018 electronic searches
Cochrane Injuries Group Specialised Register & Cochrane Central Register of Controlled Trials (CENTRAL, the Cochrane Library)
(all years to Issue 10, 2018)
#1 MESH DESCRIPTOR iron EXPLODE ALL TREES
#2 MeSH descriptor: [Iron Compounds] explode all trees
#3 iron:TI,AB,KY
#4 (((ferric OR ferrous):TI,AB,KY
#5 MeSH descriptor: [Hematinics] explode all trees
#6 (#1 OR #2 OR #3 OR #4 OR #5)
#7 MESH DESCRIPTOR preoperative period EXPLODE ALL TREES
#8 MESH DESCRIPTOR preoperative care
#9 (((prior OR before) adj3 (surg* OR operat*))):TI,AB,KY
#10 (preoperat* or perioperati* or preprocedur* or periprocedur* or presurg* or perisurg* or ((pre or peri) next (operat* or procedur* or
surgi* or surgu*))):ti,ab,kw
#11 (#7 OR #8 OR #9 OR #10)
#12 (#6 AND #11)
Ovid MEDLINE(R), Ovid MEDLINE(R) In-Process & Other Non-Indexed Citations, Ovid MEDLINE(R) Daily and Ovid OLDMEDLINE(R)
(all years to 30 July 2018)
1. exp Iron/
2. exp Iron Compounds/
3. iron.ab,ti,kf.





9. (anaemi* or anemi*).ti,ab,kf.
10. exp Blood Transfusion/
11. transfusion.ab.
12. or/7-11
13. (preoperat* or perioperati* or preprocedur* or periprocedur* or presurg* or perisurg* or ((pre or peri) adj (operat* or procedur* or
surgi* or surgu*))).ti,ab,kf.
14. ((prior or before) adj3 (surg* or operat*)).ab,ti,kf.
15. exp Preoperative Period/
16. Preoperative Care/
17 or/13-16
18 (6 and 12 and 17)
19. (randomi#ed or randomi#ation).ab,ti.
20. randomized controlled trial.pt.
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21. controlled clinical trial.pt.
22. placebo.ab.





28. (animals not (humans and animals)).sh.
29. 27 not 28
30. (18 and 29)




4. (ferric or ferrous).ti,ab,kw.
5. exp antianemic agent/
6. or/1-5
7. exp Anemia/
8. (anaemi* or anemi*).ti,ab,kw.
9. exp Blood Transfusion/
10. transfusion.ab.
11. or/7-10
12. (preoperat* or perioperati* or preprocedur* or periprocedur* or presurg* or perisurg* or ((pre or peri) adj (operat* or procedur* or
surgi* or surgu*))).ti,ab,kw.
13. ((prior or before) adj3 (surg* or operat*)).ab,ti,kw.
14. exp Preoperative Period/
15. or/12-14
16. (randomi#ed or randomi#ation).ab,ti.
17. randomized controlled trial/
18. (RCT or (random* adj3 (administ* or allocat* or assign* or class* or control* or determine* or divide* or distribut* or expose* or fashion*
or number* or place* or recruit* or subsitut* or treat*))).ab,kw.
19. placebo/
20. placebo.ab.
21. randomly.mp. or "at random".ab.
22. trial.ti.
23. or/16-22
24. exp animal/ not (exp human/ and exp animal/)
25. 23 not 24
26. 6 and 11 and 15 and 25
PubMed (to 30 July 2018)
(((((((("Comparative Study"[Publication Type]) OR "Randomized Controlled Trial"[Publication Type]) OR "Controlled Clinical Trial"[Pub-
lication Type])) OR (((((((randomized[Title/Abstract]) OR randomised[Title/Abstract]) OR placebo[Title/Abstract]) OR randomly[Title/Ab-
stract]) OR trial[Title/Abstract]) OR groups[Title/Abstract]) OR group[Title/Abstract]))) NOT (("Animals"[Mesh]) NOT ("Animals"[Mesh] AND
"Humans"[Mesh])))) AND (((((((("preoperative surgery"[Title/Abstract]) OR "before surgery"[Title/Abstract]) OR "before surgical interven-
tion"[Title/Abstract]) OR "before operation"[Title/Abstract])) OR (("Preoperative Period"[Mesh]) OR "Preoperative Care"[Mesh:noexp])))
AND (((((iron[Title/Abstract]) OR Ferrous compound*[Title/Abstract]) OR ferric compound*[Title/Abstract])) OR ((("Iron"[Mesh]) OR "Ferric
Compounds"[Mesh]) OR "Ferrous Compounds"[Mesh])))
Web of Science Indexes
SCI-EXPANDED, SSCI, A&HCI, CPCI-S, CPCI-SSH, ESCI (all years to 3 November 2016)
Topic search
#1 (iron or ferric or ferrous)
#2 (preoperat* or perioperati* or preprocedur* or periprocedur* or presurg* or perisurg*)
#3 (pre-operat* or peri-operati* or pre-procedur* or peri-procedur* or pre-surg* or peri-surg*)
#4 (anemi* or anaemi* or transfus*)
#5 (#1 and (#2 or #3) and #4)
#6 (RCT or random* or placebo)
#7 (((singl* OR doubl* OR trebl* OR tripl*) SAME (blind* OR mask*)))
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#8 (trial)
#9 (#6 or #7 or #8)
#10 (#4 and #9)
ClinicalTrials.gov 30 July 2018
Basic Search: IRON AND (PREOPERATIVE OR PERIOPERATIVE OR PERIPROCEDURAL OR PRE-OPERATIVE OR PERI-OPERATIVE OR PERI-PRO-
CEDURAL)
WHO International Clinical Trials Registry Platform (ICTRP) Search Portal 30 July 2018
Basic Search: ANEMIA AND IRON AND PREOPERATIVE OR ANEMIA AND IRON AND PERIOPERATIVE OR ANEMIA AND IRON AND PERIPROCE-
DURAL OR ANEMIA AND IRON AND PRE-OPERATIVE OR ANEMIA AND IRON AND PERI-OPERATIVE OR ANEMIA AND IRON AND PERI-PROCE-
DURAL OR ANAEMIA AND IRON AND PREOPERATIVE OR ANAEMIA AND IRON AND PERIOPERATIVE OR ANAEMIA AND IRON AND PERIPRO-
CEDURAL OR ANAEMIA AND IRON AND PRE-OPERATIVE OR ANAEMIA AND IRON AND PERI-OPERATIVE OR ANAEMIA AND IRON AND PERI-
PROCEDURAL
Appendix 2. Search strategies for 28 November 2019 electronic searches
Cochrane Injuries Group Specialised Register & Cochrane Central Register of Controlled Trials (CENTRAL, the Cochrane Library)
(all years to 28 November 2019)
#1 MeSH descriptor: [Iron] in all MeSH products
#2 MeSH descriptor: [Iron Compounds] explode all trees
#3 iron:TI,AB,KW
#4 (ferric OR ferrous):TI,AB,KW
#5 MeSH descriptor: [Hematinics] in all MeSH products
#6 (#1 OR #2 OR #3 OR #4 OR #5)
#7 MeSH descriptor: [Preoperative Period] explode all trees
#8 MeSH descriptor: [Preoperative Care] explode all trees
#9 ((prior OR before) near/3 (surg* OR operat*)):TI,AB,KW
#10 (preoperat* or perioperati* or preprocedur* or periprocedur* or presurg* or perisurg* or ((pre or peri) next (operat* or procedur* or
surgi* or surgu*))):ti,ab,kw
#11 (#7 OR #8 OR #9 OR #10)
#12 (#6 AND #11)
Ovid MEDLINE(R), Ovid MEDLINE(R) In-Process & Other Non-Indexed Citations, Ovid MEDLINE(R) Daily and Ovid OLDMEDLINE(R)
(all years to 28 November 2019)
1. exp Iron/
2. exp Iron Compounds/
3. iron.ab,ti,kf.





9. (anaemi* or anemi*).ti,ab,kf.
10. exp Blood Transfusion/
11. transfusion.ab.
12. or/7-11
13. (preoperat* or perioperati* or preprocedur* or periprocedur* or presurg* or perisurg* or ((pre or peri) adj (operat* or procedur* or
surgi* or surgu*))).ti,ab,kf.
14. ((prior or before) adj3 (surg* or operat*)).ab,ti,kf.
15. exp Preoperative Period/
16. Preoperative Care/
17. or/13-16
18. 6 and 12 and 17
19. (randomi#ed or randomi#ation).ab,ti.
20. randomized controlled trial.pt.
21. controlled clinical trial
22. placebo.ab.
23. clinical trials as topic.sh.
24. randomly.ab.
25. trial.ti.
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26. Comparative Study/
27. or/19-26
28. (animals not (humans and animals)).sh.
29. 27 not 28
30. 18 and 29




4. (ferric or ferrous).ti,ab,kw.
5. exp antianemic agent/
6. or/1-5
7. exp Anemia/
8. (anaemi* or anemi*).ti,ab,kw.
9. exp Blood Transfusion/
10. transfusion.ab.
11. or/7-10
12.(preoperat* or perioperati* or preprocedur* or periprocedur* or presurg* or perisurg* or ((pre or peri) adj (operat* or procedur* or surgi*
or surgu*))).ti,ab,kw.
13. ((prior or before) adj3 (surg* or operat*)).ab,ti,kw.
14. exp Preoperative Period/
15. or/12-14
16. (randomi#ed or randomi#ation).ab,ti.
17. randomized controlled trial/
18. (RCT or (random* adj3 (administ* or allocat* or assign* or class* or control* or determine* or divide* or distribut* or expose* or fashion*
or number* or place* or recruit* or subsitut* or treat*))).ab,kw.
19. placebo/
20. placebo.ab.
21. randomly.mp. or "at random".ab.
22. trial.ti.
23. or/16-22
24. exp animal/ not (exp human/ and exp animal/)
25. 23 not 24
26. 6 and 11 and 15 and 25
PubMed (to 28 November 2019)
(((((((("Comparative Study"[Publication Type]) OR "Randomized Controlled Trial"[Publication Type]) OR "Controlled Clinical Trial"[Pub-
lication Type])) OR (((((((randomized[Title/Abstract]) OR randomised[Title/Abstract]) OR placebo[Title/Abstract]) OR randomly[Title/Ab-
stract]) OR trial[Title/Abstract]) OR groups[Title/Abstract]) OR group[Title/Abstract]))) NOT (("Animals"[Mesh]) NOT ("Animals"[Mesh] AND
"Humans"[Mesh])))) AND (((((((("preoperative surgery"[Title/Abstract]) OR "before surgery"[Title/Abstract]) OR "before surgical interven-
tion"[Title/Abstract]) OR "before operation"[Title/Abstract])) OR (("Preoperative Period"[Mesh]) OR "Preoperative Care"[Mesh:noexp])))
AND (((((iron[Title/Abstract]) OR Ferrous compound*[Title/Abstract]) OR ferric compound*[Title/Abstract])) OR ((("Iron"[Mesh]) OR "Ferric
Compounds"[Mesh]) OR "Ferrous Compounds"[Mesh])))
Web of Science Indexes
SCI-EXPANDED, SSCI, A&HCI, CPCI-S, CPCI-SSH, ESCI (all years to 28 November 2019)
Topic search
#1 (iron or ferric or ferrous)
#2 (preoperat* or perioperati* or preprocedur* or periprocedur* or presurg* or perisurg*)
#3 (pre-operat* or peri-operati* or pre-procedur* or peri-procedur* or pre-surg* or peri-surg*)
#4 (anemi* or anaemi* or transfus*)
#5 (#3 OR #2)
#6 (#4 AND #1)
#7 #6 and #5
#8 (RCT or random* or placebo)
#9 (((singl* OR doubl* OR trebl* OR tripl*) SAME (blind* OR mask*)))
#10 (trial)
#11 (#10 or #9 or #8)
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ClinicalTrials.gov 28 November 2019
Basic search: IRON AND (PREOPERATIVE OR PERIOPERATIVE OR PERIPROCEDURAL OR PRE-OPERATIVE OR PERI-OPERATIVE OR PERI-PRO-
CEDURAL)
WHO International Clinical Trials Registry Platform (ICTRP) Search Portal 28 November 2019
Basic search: ANEMIA AND IRON AND PREOPERATIVE OR ANEMIA AND IRON AND PERIOPERATIVE OR ANEMIA AND IRON AND PERIPROCE-
DURAL OR ANEMIA AND IRON AND PRE-OPERATIVE OR ANEMIA AND IRON AND PERI-OPERATIVE OR ANEMIA AND IRON AND PERI-PROCE-
DURAL OR ANAEMIA AND IRON AND PREOPERATIVE OR ANAEMIA AND IRON AND PERIOPERATIVE OR ANAEMIA AND IRON AND PERIPRO-
CEDURAL OR ANAEMIA AND IRON AND PRE-OPERATIVE OR ANAEMIA AND IRON AND PERI-OPERATIVE OR ANAEMIA AND IRON AND PERI-
PROCEDURAL
W H A T ' S   N E W
 
Date Event Description
6 December 2019 New search has been performed The results from the search run on 30 July 2018 have been incor-
porated into the review. Three new studies, involving 258 partici-
pants, are included in the review.
A top-up search was run on 28 November 2019; one additional
study is awaiting classification.
6 December 2019 New citation required and conclusions
have changed
The results have changed. The authors of the review have
changed.
 
C O N T R I B U T I O N S   O F   A U T H O R S
AM, BK, AS, JS: main contribution to the study concepts and study design
ON, BK, HA: main contribution to the data acquisition, analysis, interpretation and manuscript preparation
KN: main contribution to statistical support
MB, AA: main contribution to supervision and revision of the manuscript
HA: checked all extracted data, 'Risk of bias' assessments and conclusions
D E C L A R A T I O N S   O F   I N T E R E S T
The lead author, ON, is in breach of Cochrane Commercial policy due to having received honoraria and travel support from Pharmacosmos
(Denmark) and Vifor Pharma (Switzerland) within the last three years. The Cochrane Funding Arbiter's panel recommended that:
• a new, unconflicted author should check the data extraction and risk of bias tables;
• a member of the editorial group should check that this has been done;
• the final published version of the review should include a clear statement that the lead author is in breach of Cochrane Commercial
policy together with a description of the Funding Arbiter Panel’s recommendation and the actions taken.
A new unconflicted author, HA, has independently checked all data extraction, 'Risk of bias' tables and conclusions, including Keeler 2017,
to ensure there was no bias in the review findings, and has agreed that the reporting of the review was valid. Elizabeth Royle (Editor/Man-
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D I F F E R E N C E S   B E T W E E N   P R O T O C O L   A N D   R E V I E W
In the previous version of this review we assessed short-term mortality as death within 30 days of surgery, and long-term mortality as
death a year or more after surgery (Ng 2015b). For this 2019 update of the review, we have adjusted long-term mortality to death from 31
days up to one year after surgery.
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Medical Subject Headings (MeSH)
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